全文获取类型
收费全文 | 1301篇 |
免费 | 106篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 8篇 |
妇产科学 | 19篇 |
基础医学 | 173篇 |
口腔科学 | 12篇 |
临床医学 | 125篇 |
内科学 | 474篇 |
皮肤病学 | 6篇 |
神经病学 | 91篇 |
特种医学 | 119篇 |
外科学 | 81篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 49篇 |
眼科学 | 4篇 |
药学 | 142篇 |
中国医学 | 1篇 |
肿瘤学 | 95篇 |
出版年
2024年 | 4篇 |
2023年 | 24篇 |
2022年 | 11篇 |
2021年 | 27篇 |
2020年 | 32篇 |
2019年 | 40篇 |
2018年 | 41篇 |
2017年 | 32篇 |
2016年 | 44篇 |
2015年 | 44篇 |
2014年 | 60篇 |
2013年 | 62篇 |
2012年 | 100篇 |
2011年 | 97篇 |
2010年 | 67篇 |
2009年 | 44篇 |
2008年 | 83篇 |
2007年 | 89篇 |
2006年 | 82篇 |
2005年 | 77篇 |
2004年 | 79篇 |
2003年 | 67篇 |
2002年 | 68篇 |
2001年 | 11篇 |
2000年 | 6篇 |
1999年 | 11篇 |
1998年 | 13篇 |
1997年 | 12篇 |
1996年 | 6篇 |
1995年 | 11篇 |
1994年 | 8篇 |
1993年 | 7篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1990年 | 5篇 |
1989年 | 10篇 |
1988年 | 4篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1975年 | 3篇 |
1974年 | 1篇 |
1970年 | 2篇 |
排序方式: 共有1413条查询结果,搜索用时 31 毫秒
31.
Simplified negative pressure wound therapy: clinical evaluation of an ultraportable,no‐canister system 下载免费PDF全文
Donald A Hudson Kevin G Adams Adriaan Van Huyssteen Robin Martin Elizabeth M Huddleston 《International wound journal》2015,12(2):195-201
The aim of this study was to evaluate a prototype negative pressure wound therapy (NPWT) system that has been developed to simplify NPWT for wounds at the lower end of the acuity scale. The new device has a single preset pressure of ?80 mmHg, is single use and operates without an exudate canister. The disposable NPWT system (PICO?) was tested in a prospective, non‐comparative, multicentre clinical trial to assess device functionality and clinical acceptance. Twenty patients were recruited for a maximum treatment period of 14 days. The NPWT devices were fitted with data log chips to enable longitudinal assessment of negative pressure and leak rates during therapy. Sixteen (80%) patients had closed surgical wounds, two (10%) patients had traumatic wounds and two (10%) patients received meshed split thickness skin grafts. The mean study duration was 10·7 days (range: 5–14 days) and the mean dressing wear time per individual patient was 4·6 days (range: 2–11). Fifty‐five percent of wounds had closed by the end of the 14‐day study or earlier, with a further 40% of wounds progressing to closure. Real‐time pressure monitoring showed continuous delivery of NPWT. Three cases are discussed representing different wound locations and different patient factors that can increase the risk of post‐surgical complications. Clinical studies of the disposable NPWT system confirmed the ability of the simplified single‐use device to function consistently over the expected wear time. The anticipated reduced costs, ease of use and increased mobility of patients using this system may enable NPWT benefits to be available to a greater proportion of patients. 相似文献
32.
Pim van der Harst Gerrit van der Steege Rudolf A de Boer Adriaan A Voors Alistair S Hall Marcel J Mulder Wiek H van Gilst Dirk J van Veldhuisen 《Journal of the American College of Cardiology》2007,49(13):1459-1464
OBJECTIVES: This study sought to test the hypothesis that patients with chronic heart failure (CHF) have shorter telomeres compared with age-balanced and gender-balanced healthy individuals. BACKGROUND: Telomere length is considered to be a marker of biological aging. Chronic heart failure might be viewed as a condition associated with accelerated biological aging. METHODS: The telomere length ratio of leukocytes was determined prospectively by a quantitative polymerase chain reaction-based method in a case-control setting involving 803 participants: 183 healthy individuals and 620 CHF patients, ages 40 to 80 years, New York Heart Association functional class II to IV, and left ventricular ejection fraction of 0.40 or less. RESULTS: The median telomere length ratio was 0.64 (interquartile range [IQR] 0.47 to 0.88) in CHF patients compared with 1.05 (IQR 0.86 to 1.29) in control patients (p < 0.001). The telomere length ratio in CHF patients related to severity of disease (median value [IQR] of patients with New York Heart Association class II, III, or IV function was 0.67 [0.48 to 0.92], 0.63 [0.46 to 0.86], and 0.55 [0.46 to 0.75], respectively; p for trend <0.05). In addition, telomeres were shorter in patients with an ischemic compared with a nonischemic etiology of CHF. Patients with none, 1 (coronary, cerebral, or peripheral vascular disease), 2 (any combination of the previous), or 3 atherosclerotic manifestations had a median (IQR) telomere length of 0.72 (0.51 to 1.01), 0.65 (0.48 to 0.87), 0.48 (0.39 to 0.72), and 0.43 (0.27 to 0.67), respectively (p for trend <0.001). CONCLUSIONS: Telomere length is shorter in patients with CHF compared with age-balanced and gender-balanced control patients, and related to the severity of disease. In addition, telomere length was incrementally shorter according to the presence and extent of atherosclerotic disease manifestations. 相似文献
33.
34.
Sex‐specific cardiovascular structure and function in heart failure with preserved ejection fraction
Mauro Gori Carolyn S. P. Lam Deepak K. Gupta Angela B. S. Santos Susan Cheng Amil M. Shah Brian Claggett Michael R. Zile Elisabeth Kraigher‐Krainer Burkert Pieske Adriaan A. Voors Milton Packer Toni Bransford Martin Lefkowitz John J. V. McMurray Scott D. Solomon for the PARAMOUNT Investigators 《European journal of heart failure》2014,16(5):535-542
35.
Burkert Pieske Carsten Tschpe Rudolf A. de Boer Alan G. Fraser Stefan D. Anker Erwan Donal Frank Edelmann Michael Fu Marco Guazzi Carolyn S.P. Lam Patrizio Lancellotti Vojtech Melenovsky Daniel A. Morris Eike Nagel Elisabeth Pieske-Kraigher Piotr Ponikowski Scott D. Solomon Ramachandran S. Vasan Frans H. Rutten Adriaan A. Voors Frank Ruschitzka Walter J. Paulus Petar Seferovic Gerasimos Filippatos 《European journal of heart failure》2020,22(3):391-412
Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the ‘HFA–PEFF diagnostic algorithm’. Step 1 (P=Pre‐test assessment) is typically performed in the ambulatory setting and includes assessment for heart failure symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non‐cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular (LV) ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e′), LV filling pressure estimated using E/e′, left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2–4 points) implies diagnostic uncertainty, in which case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2: Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF. 相似文献
36.
John R. Teerlink Beth A. Davison Gad Cotter Aldo P. Maggioni Naoki Sato Ovidiu Chioncel Georg Ertl G. Michael Felker Gerasimos Filippatos Barry H. Greenberg Peter S. Pang Piotr Ponikowski Christopher Edwards Stefanie Senger Sam L. Teichman Olav Wendelboe Nielsen Adriaan A. Voors Marco Metra 《European journal of heart failure》2020,22(2):315-329
37.
38.
Nils Bomer Niels Grote Beverborg Martijn F. Hoes Koen W. Streng Mathilde Vermeer Martin M. Dokter Jan IJmker Stefan D. Anker John G.F. Cleland Hans L. Hillege Chim C. Lang Leong L. Ng Nilesh J. Samani Jasper Tromp Dirk J. van Veldhuisen Daan J. Touw Adriaan A. Voors Peter van der Meer 《European journal of heart failure》2020,22(8):1415-1423
39.
40.